Effect of Empagliflozin 10 vs 25 mg on LV Remodeling in Diabetic Patients With Anterior STEMI With Reduced LVEF
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.
Also called NCT07169981
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT07169981
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Egypt
- Registry status
- Completed
Technical summary
Registry record NCT07169981. Randomized; double masking; primary purpose treatment. Start 2023-07-12 (actual); primary completion 2025-02-23 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Empagliflozin 10 vs 25 mg on LV Remodeling in Diabetic Patients With Anterior STEMI With Reduced LVEF
- Acronym
- EMPA-DMMI
- Condition
- Diabete Mellitus
- Condition
- Heart Failure
- Condition
- Remodeling, Left Ventricle
- Intervention (Drug)
- Empagliflozin 10 MG [Jardiance]
- Intervention (Drug)
- empagliflozin (Jardiance) 25 mg
- Lead sponsor
- Ain Shams University
Record details
- Record id
cardio:ct-nct07169981- Content hash
41e75ebcfb76b008d4de956c574615de946613acb4d569f0b6d3ab52206dbfdc